Apixaban in Thrombocytopenia

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Rushad Patell
Study ID
NCT06886516
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Deep Vein Thrombosis
  • Pulmonary Embolism and Thrombosis
  • Recurrent Venous Thromboembolism
  • Thrombocytopenia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apixaban — DRUG
    A factor Xa inhibitor, 2.5 and 5 mg tablets, by mouth per protocol.

Study Details

This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes. The name of the study drug involved in this study is: -Apixiban (a type of anticoagulant)

Key Dates

Start date
Feb 28, 2025
Status verified
Apr 2026
Primary completion
Jul 1, 2027
Completion
Jul 1, 2029

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: DOSE-ADJUSTED APIXABAN
    30 enrolled participants will complete study procedures as follows: * Baseline visit with assessments * Predetermined dose of Apixiban 2x daily for 90 days * Off treatment visit 7 days after last study drug dose * Follow up visit 6 weeks after last study drug dose

Primary Outcome Measure

Study Enrollment [ Time Frame: Up to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02215
Rushad Patell, MD
[email protected]
617-667-9179
Rushad Patell, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Beth Israel Deaconess Medical Center· Boston, MA

Related Studies